AtaiBeckley (ATAI) Receivables - Net (2023 - 2026)
AtaiBeckley's (ATAI) quarterly Receivables - Net came in at $864000.0 in Q1 2026, up 29.54% quarter-over-quarter from $667000.0 in Q4 2025.
AtaiBeckley (ATAI) Receivables - Net (2023 - 2026) Analysis & Trends
AtaiBeckley's Receivables - Net history runs 3 years deep, the most recent figure standing at $864000.0 for Q1 2026.
- On a quarterly basis, Receivables - Net changed N/A year-over-year to $864000.0 in Q1 2026; TTM through Mar 2026 was $864000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $667000.0, up 88.42% from the prior year.
- Receivables - Net grew to $864000.0 in Q1 2026 per ATAI's latest filing, from $667000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $313000.0 in Q3 2024 to a low of $46000.0 in Q3 2025.
- A 3-year average of $176000.0 and a median of $172500.0 in 2023 frame the typical range for Receivables - Net.
- Biggest YoY gain for Receivables - Net was 88.42% in 2025; the steepest drop was 88.42% in 2025.
- Year by year, Receivables - Net stood at $354000.0 in 2024, then soared by 88.42% to $667000.0 in 2025, then gained by 29.54% to $864000.0 in 2026.
- Per Business Quant, the three latest ATAI Receivables - Net figures stand at $864000.0 (Q1 2026), $667000.0 (Q4 2025), and $354000.0 (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | AtaiBeckley | 2.56 Bn | 2.56 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 864,000.00 |
| Mar 31, 2026 | 864,000.00 |
| Dec 31, 2025 | 667,000.00 |
| Dec 31, 2025 | 667,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Dec 31, 2024 | 261,000.00 |
| Dec 31, 2024 | 354,000.00 |
| Dec 31, 2024 | 354,000.00 |
| Dec 31, 2024 | 261,000.00 |
| Sep 30, 2024 | 313,000.00 |
| Sep 30, 2024 | 313,000.00 |
| Dec 31, 2023 | 84,000.00 |
| Dec 31, 2023 | 84,000.00 |